Ascendis Pharma AS (ASND NASDAQ) stock market data APIs
$160.8659
-2.4(-1.5%)
as of April 24, 2025
Ascendis Pharma AS Financial Data Overview
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Prev. Close
160.8659
Open
158.463
High
160.7184
Low
156.8967
52 wk Range
111.09-169.37
Market Cap
9 568 M
Shares Outstanding
60 125 K
Revenue
364 M
EPS
-0.64
Beta
0.536
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ascendis Pharma AS data using free add-ons & libraries
Get Ascendis Pharma AS Fundamental Data
Ascendis Pharma AS Fundamental data includes:
- Net Revenue: 364 M
- EBITDA: -273 828 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-13
- EPS/Forecast: -0.9327
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ascendis Pharma AS News
New
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2025 financial results and provide a business update on Thursd...
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
Ascendis Pharma COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2025 financial results and provide a business u...
Reddit initiated, Target downgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Stay Ahead of th...
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Ascendis Pharma A/S (ASND) been one of those stocks this year? Let's take a clos...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
